🇺🇸 Liposomal curcumin in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Dysuria — 1 report (10%)
2. Gait Disturbance — 1 report (10%)
3. Hypoaesthesia — 1 report (10%)
4. Hypoaesthesia Oral — 1 report (10%)
5. Myalgia — 1 report (10%)
6. Neuropathy Peripheral — 1 report (10%)
7. Paraesthesia — 1 report (10%)
8. Pruritus — 1 report (10%)
9. Skin Burning Sensation — 1 report (10%)
10. Skin Tightness — 1 report (10%)

Source database →

Frequently asked questions

Is Liposomal curcumin approved in United States?

Liposomal curcumin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Liposomal curcumin in United States?

University of Florida is the originator. The local marketing authorisation holder may differ — check the official source linked above.